Description
An intestine-selective FXR antagonist; glycine-conjugated form of β-muricholic acid; inhibits chenodeoxycholic acid- and GW 4064-induced expression of the FXR target genes Shp and Fgf15 at 100 μM; resistant to hydrolysis by fecal BSH isolated from gut microbiota; decreases Shp and Fgf15 mRNA expression in ileum, but not liver, and reduces ceramide levels and expression of various ceramide synthesis-related genes in ileum of mice with high-fat diet-induced obesity and db/db mice at 10 mg/kg; prevents weight gain, reduces blood glucose levels, and increases insulin sensitivity as well as prevents development of cholestasis and necrotic lesions in liver of mice with high-fat diet-induced obesity
Formal name: N-[(3α,5β,6β,7β)-3,6,7-trihydroxy-24-oxocholan-24-yl]-glycine
Synonyms: Gly-MCA|GβMCA
Molecular weight: 465.6
CAS: 66225-78-3
Purity: ≥95%
Formulation: A crystalline solid